Soluble guanylate cyclase as a direct target for pharmacologic mitigation of chronic kidney disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39984251.
- Also identified by DOI 10.1016/j.kint.2024.12.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a preclinical rat study, Lichtenberger et al. show that BAY-60-2770, a drug that activates soluble guanylyl cyclase, often rendered inactive by oxidative stress, mitigates kidney inflammation, injury, and fibrosis, likely by vascular effects after ischemia-reperfusion. Kidney perfusion, overall vascular reactivity, and medullary microvascular diameter are improved by the drug at doses that do not alter blood pressure. Soluble guanylyl cyclase is an attractive and potentially unexploited target to halt progression of chronic kidney disease.
Medical subject headings
- Renal Insufficiency, Chronic
- Kidney
- Benzoates
- Guanylate Cyclase